Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | PDE4A | P27815 | 18/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 17/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 17/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 17/20 | 0.56 |
| ▸ | VEGFA | P15692 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3373532 | 0.95 | MAPT (0.69) | MAPTKDM4ETHRBPDE4APDE4B | |
| SCHEMBL3377462 | 0.85 | MAPT (0.48) | MAPTKDM4ETHRBPDE4APDE4B | |
| SCHEMBL3374185 | 0.84 | KDM4E (0.64) | MAPTKDM4ETHRBPDE4APDE4B | |
| SCHEMBL5823060 | 0.81 | PDE4A (0.77) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3770826 | 0.81 | PDE4A (0.54) | MAPTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8523190 | 0.78 | PDE4A (0.58) | MAPTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3374951 | 0.78 | KDM4E (0.68) | MAPTKDM4ETHRBPDE4APDE4B | |
| SCHEMBL3370231 | 0.77 | PDE4A (0.52) | MAPTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL497727 | 0.76 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8632255 | 0.76 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324091-A1 | Pyrazolone Derivative | KOWA COMPANY, LTD. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2172458-A1 | PYRAZOLONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324091-A1 | Pyrazolone Derivative | SERPINE1, SERPINC1, TFPI | MAPT 2810/4885KDM4E 4172/4885THRB 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.